Business Context and Reporting Period
Filing identity: The submitted filing is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It is an unaudited Form 10-Q for the quarter and nine months ended September 30, 2016.
Selecta was a clinical-stage biopharmaceutical company developing synthetic vaccine particle technology to modulate immune responses. Its lead candidate, SEL-212, was in a Phase 1/2 clinical program for refractory and chronic tophaceous gout. The company had no approved products or product sales; revenue consisted of grants and collaboration arrangements.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Grant and collaboration revenue | $1.0 million, down 35% | $5.2 million, up 33% |
| Research and development expense | $6.0 million, up 10% | $18.7 million, up 18% |
| General and administrative expense | $2.5 million, up 14% | $7.3 million, up 16% |
| Loss from operations | $7.5 million | $20.8 million |
| Net loss | $7.7 million | $22.1 million |
| Net loss attributable to common stockholders | $7.7 million | $26.7 million |
| Basic and diluted loss per share | $0.43 | $3.39 |
Approximate operating margins were negative 713% for the quarter and negative 404% for the nine-month period, reflecting the company’s development-stage profile and limited revenue base. Accumulated deficit was $137.5 million at September 30, 2016.
- Cash and cash equivalents were $59.5 million, compared with $32.3 million at December 31, 2015.
- Short-term deposits and investments were $19.8 million, compared with $4.1 million at year-end 2015.
- Total assets were $85.8 million and stockholders’ equity was $65.4 million.
- Outstanding term-loan principal was $12.0 million, bearing interest at approximately 8.1%. Principal payments were scheduled to begin in February 2017, with maturity in July 2019.
- Cash used in operating activities was $21.2 million for the first nine months, versus $14.8 million in the prior-year period.
- Cash used in investing activities was $16.9 million, principally reflecting purchases of short-term investments.
- Cash provided by financing activities was $64.9 million, primarily from the June 2016 initial public offering and July 2016 overallotment exercise.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue declined $0.6 million, primarily because of lower Sanofi collaboration revenue and timing of other grant and collaboration activities. Nine-month revenue increased $1.3 million, driven mainly by higher NIH grant revenue.
- Research and development expense increased $0.5 million for the quarter and $2.9 million for the nine months, reflecting advancement of SEL-212 into clinical trials, increased internal personnel costs, stock-based compensation and spending on other pipeline programs.
- General and administrative expense increased $0.3 million for the quarter and $1.0 million for the nine months, driven by public-company compliance, consulting, patent, professional and travel costs.
- The company completed its IPO in June 2016, raising approximately $64.5 million in net proceeds. All outstanding convertible preferred stock converted into common stock, materially increasing common shares outstanding.
- Cash increased substantially following the IPO, but operating cash burn also increased as clinical development activities expanded.
Guidance, Outlook, Risks and Unusual Items
- Management expected continuing operating losses and increasing research and development and general and administrative expenses for the foreseeable future.
- Based on its operating plan, management estimated that cash, investments and restricted cash at September 30, 2016 would fund operations and capital expenditures into the first quarter of 2018. This estimate was expressly subject to assumptions that could prove inaccurate.
- As a subsequent event, Sanofi notified the company on November 9, 2016 that it would terminate the collaboration effective May 8, 2017. The company did not expect further Sanofi collaboration payments, although approximately $2.2 million of deferred Sanofi revenue at September 30, 2016 was expected to be recognized during the termination period.
- The company intended to exercise its right to reacquire development programs under the Sanofi agreement, which would leave it responsible for future development and clinical costs for any programs it pursued.
- Key risks included the need for additional capital, uncertain clinical and regulatory outcomes, potential clinical-trial delays, reliance on third-party manufacturers and CROs, dependence on 3SBio in China for pegsiticase, intellectual-property risks, foreign-currency exposure and loss of collaboration funding.
- The $12.0 million secured credit facility included restrictive covenants and default provisions, including a subjective material-adverse-change acceleration clause. No default had occurred as of the filing date.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls were effective as of September 30, 2016.
Most Important Facts for Investors to Verify
- Confirm the correct issuer: the source filing is Selecta Biosciences, Inc., despite the request identifying Cartesian Therapeutics, Inc.
- Verify the effect of Sanofi’s post-quarter termination on revenue, deferred revenue recognition, development obligations and projected cash runway.
- Assess whether the reported cash runway into the first quarter of 2018 remains supportable after the loss of Sanofi funding and any expansion of clinical programs.
- Review SEL-212 clinical-trial progress, safety data, enrollment, regulatory requirements and anticipated development costs.
- Evaluate the $12.0 million secured debt, scheduled amortization beginning in 2017, covenants and potential acceleration provisions.
- Monitor the company’s operating cash burn and its potential need for additional equity, debt, grant or collaboration financing.